A detailed history of Two Sigma Investments, LP transactions in Immatics N.V. stock. As of the latest transaction made, Two Sigma Investments, LP holds 106,669 shares of IMTX stock, worth $730,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106,669
Previous 130,999 18.57%
Holding current value
$730,682
Previous $1.52 Million 20.04%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.93 - $12.92 $265,926 - $314,343
-24,330 Reduced 18.57%
106,669 $1.22 Million
Q2 2024

Aug 14, 2024

SELL
$9.78 - $13.49 $871,632 - $1.2 Million
-89,124 Reduced 40.49%
130,999 $1.52 Million
Q1 2024

May 15, 2024

SELL
$10.23 - $12.94 $1.17 Million - $1.47 Million
-113,893 Reduced 34.1%
220,123 $2.31 Million
Q4 2023

Feb 14, 2024

BUY
$7.36 - $10.89 $1.84 Million - $2.72 Million
249,788 Added 296.56%
334,016 $3.52 Million
Q3 2023

Nov 14, 2023

SELL
$11.01 - $12.62 $1.62 Million - $1.86 Million
-147,573 Reduced 63.66%
84,228 $975,000
Q2 2023

Aug 14, 2023

BUY
$5.92 - $12.72 $998,650 - $2.15 Million
168,691 Added 267.3%
231,801 $2.67 Million
Q1 2023

May 15, 2023

BUY
$6.74 - $9.44 $78,359 - $109,749
11,626 Added 22.58%
63,110 $435,000
Q4 2022

Feb 14, 2023

BUY
$8.05 - $11.58 $96,447 - $138,739
11,981 Added 30.33%
51,484 $448,000
Q3 2022

Nov 14, 2022

BUY
$3.31 - $13.06 $130,754 - $515,909
39,503 New
39,503 $395,000
Q4 2021

Feb 14, 2022

SELL
$10.81 - $14.38 $141,254 - $187,903
-13,067 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$11.58 - $15.46 $10,201 - $13,620
-881 Reduced 6.32%
13,067 $170,000
Q2 2021

Aug 16, 2021

BUY
$10.43 - $12.81 $145,477 - $178,673
13,948 New
13,948 $162,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $522M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.